怎么也得最近的抗病毒治疗的进步影响病毒相关性肝癌的管

StephenW

How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma?
Article in Expert Opinion on Pharmacotherapy · February 2016
DOI: 10.1517/14656566.2016.1149165

    1st Chia-Chi Wang
    2nd Jia-Horng Kao
    50.54 · National Taiwan University

Abstract
Introduction:
Whether the recent advances in antiviral therapy including nucleos(t)ide analogue (NA) or interferon (IFN) impacts the management of patients with virus-related hepatocellular carcinoma (HCC) remains unclear. Area covered: The beneficial effects of antiviral therapy on HCC patients receiving curative treatment, transhepatic arterial chemoembolization (TACE), or radiotherapy are reviewed and discussed. Expert opinion: For patients with HCV-related HCC after curative treatment, interferon (IFN)-based therapy has been shown to improve the survival and reduces the risk of HCC recurrence. However, it carries the risk of adverse effects, especially in cirrhotic patients. Therefore, the benefit of IFN should be weighted against its risk in each individual. For patients with HBV-related HCC after curative treatments, antiviral treatment with NA has been found to improve liver function, overall survival, and possibly reduce the risk of HCC recurrence. In contrast, these benefits were not consistently observed in those receiving IFN treatment. In HCC patients receiving palliative TACE or radiotherapy, HBV reactivation occurs in a small proportion of them, and preemptive NA treatment can reduce the risk of hepatitis flare due to viral reactivation. Therefore, NA treatment after curative treatments or TACE is strongly recommended for HCC patients with high viral load (HBV DNA> 2000 IU/mL).

StephenW

怎么也得最近的抗病毒治疗的进步影响病毒相关性肝癌的管理？
文章中专家意见的药物治疗·2016年二月
DOI：10.1517 / 14656566.2016.1149165

    1王嘉驰往
    第二佳鸿花王
    50.54·国立台湾大学

抽象
介绍：
无论是在抗病毒治疗的最新进展，包括核苷（酸）类似物IDE（NA）或干扰素（IFN）影响患者的管理与病毒相关的肝细胞癌（HCC）仍不清楚。覆盖区域：抗病毒治疗对接受根治性治疗肝癌患者的有益作用，肝动脉化疗栓塞（TACE），或放疗进行审查和讨论。专家意见：对于患者治愈性治疗后的HCV相关的HCC，干扰素（IFN）系疗法已被证实可以改善生存和降低肝癌复发的风险。然而，它携带的不利影响的风险，尤其是在肝硬化患者。因此，IFN的利益应针对其在每一个人的风险加权。患者治愈性治疗后HBV相关HCC，用NA抗病毒治疗已被发现改善肝功能，整体存活率，并有可能降低肝癌复发的风险。相反，这些优势没有得到一贯那些接受干扰素治疗观察。在接受姑息TACE或放疗肝癌患者，HBV再发生在他们中的一小部分，并抢占NA可以治疗肝炎暴发的风险，减少因病毒复发。因此，NA治疗治愈性治疗或TACE治疗后强烈建议肝癌患者具有高病毒载量（HBV DNA> 2000 IU / mL）中。